Argenx Projects $4.15 Billion in Sales by 2025 and Plans Four Phase 3 Studies
Dutch biotechnology group argenx has announced preliminary net sales of $4.15 billion for fiscal year 2025, a 90% increase year-over-year. The company is currently treating approximately 19,000 patients with its drug VYVGART and expects four registration study results in 2026.
Financial Performance and Patient Reach
According to the press release, argenx recorded preliminary global net sales of $4.15 billion for the year 2025, marking a 90% increase from the previous fiscal year. The fourth quarter of 2025 alone generated approximately $1.29 billion in revenue. The group reports that VYVGART, its flagship treatment approved for three indications including generalized myasthenia and chronic inflammatory demyelinating polyneuropathy, is currently prescribed to about 19,000 patients worldwide. The company notes that these financial figures are preliminary, unaudited, and subject to adjustment before the full results are published in February 2026.
Upcoming Clinical Study Results
The group expects four registration study results in 2026 for efgartigimod and empasiprubart. Argenx specifically aims to expand the indication of VYVGART to seronegative generalized myasthenia, with a planned launch by the end of 2026 pending approval. The group also anticipates publishing phase 3 data for ocular myasthenia in the first quarter of 2026 and for primary immune thrombocytopenic purpura in the fourth quarter of 2026, aiming for a launch in the United States. Regarding empasiprubart, an antibody targeting C2, the initial phase 3 results for multifocal motor neuropathy are expected in the fourth quarter of 2026.
Pipeline Development and Executive Changes
According to the press release, argenx anticipates that its pipeline will include ten molecules in clinical development by the end of 2026, four of which will be in phase 3. The group advanced four new molecules in 2025, including ARGX-213 and ARGX-124 targeting FcRn, ARGX-109 targeting IL-6, and ARGX-121 targeting IgA. Three new molecules are expected to enter phase 1 in 2026. Additionally, the company indicates that Karen Massey, currently Chief Operating Officer, will succeed Tim Van Hauwermeiren as CEO. He will take on the role of non-executive chairman of the board, pending shareholder approval at the general meeting on May 6, 2026. Sandrine Piret-Gérard has been appointed as the director of commercialization.
